Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02783300 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 297
- Enrollment target
NCT02783300 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 297 participants.
The verdict
NCT02783300, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 297 participants
- Enrollment target
Study Summary
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).
Interventions
- DRUG Pembrolizumab
- DRUG GSK3326595
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2023-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02783300
The ClinicalTrials.gov registry entry for NCT02783300 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02783300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02783300 about?
NCT02783300 is a clinical study titled "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma". This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset ...
What is the current status of trial NCT02783300?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 297 participants. The study started on 2016-08-30. Estimated completion is 2023-08-30.
What interventions are being tested in trial NCT02783300?
The interventions under investigation include: Pembrolizumab (DRUG), GSK3326595 (DRUG).
Who is sponsoring clinical trial NCT02783300?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.